BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Romidepsin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Romidepsin\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06963346-3218@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Romidepsin: Phase 1 readout est. (NCT06963346)
DESCRIPTION:Romidepsin\, phase 1.\nStudy: Study Investigating Intravesical 
 HDAC Inhibition to Improve Response to Immuno-Oncology Agents\nEstimated p
 rimary completion: April 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/romidepsin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06963346
URL:https://assetmemo.bio/drug/romidepsin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747236-3218@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20280602
DTEND;VALUE=DATE:20280603
SUMMARY:Romidepsin: Phase 2 readout est. (NCT04747236)
DESCRIPTION:Romidepsin\, phase 2.\nStudy: Randomized Phase IIB Trial of Ora
 l Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL\nEstima
 ted primary completion: 2 June 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/romidepsin#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04747236
URL:https://assetmemo.bio/drug/romidepsin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
